Skip to main content
SpringerLink
Log in

The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy; Use as a Single Agent in Susceptible Patients; Techniques Used to Identify Susceptible Patients

  • Protocol
  • First Online:
Poly(ADP-ribose) Polymerase

Part of the book series: Methods in Molecular Biology ((MIMB,volume 780))

  • 2593 Accesses

Abstract

This chapter describes some of the techniques in use in our laboratories for the investigation of PARP inhibitors in clinical medicine. More specifically, we are involved in investigating the utility of PARP inhibitors in the treatment of hematopoietic malignancies. We are also actively investigating the properties of the PARP systems in cell biology. We begin the chapter with a very brief history of the invention and use of PARP inhibitors. We then explain the underlying logic of the use of PARP inhibitors either in combination with chemo- or radiotherapy or as single agents used alone. We then provide in full detail the protocols that we use to study PARP inhibitors in cell biology to identify patients that should be susceptible to PARP inhibitor treatment and to manage and investigate these patients throughout their treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Doly J, Petek F (1966) Étude de la structure d’un compose “poly (ADP-ribose)” synthétisé par des extraits nucléares de foie de poulet. C R Hebd Seances Acad Sci Ser D Sci Nat 263:1341–1344

    CAS  Google Scholar 

  2. Chambon P, Weill JD, Doly J, Strosser MT, Mandel P (1966) On the formation of a novel adenylic compound by enzymatic extracts of liver nuclei. Biochem Biophys Res Commun 25:638–643

    Article  CAS  Google Scholar 

  3. Sugimura T, Fujimura S, Hasegawa S, Kawamura Y (1967) Polymerization of the adenosine 5′-diphosphate ribose moiety of NAD by rat liver nuclear enzyme. Biochim Biophys Acta 138:438–441

    Article  PubMed  CAS  Google Scholar 

  4. Nishizuka Y, Ueda K, Nakazawa K, Hayaishi O (1967) Studies on the polymer of adenosine diphosphate ribose. 1. Enzymic formation from nicotinamide dinucleotide in mammalian nuclei. J Biol Chem 242:3164–3171

    PubMed  CAS  Google Scholar 

  5. Roitt IM (1956) The inhibition of carbohydrate metabolism in ascites-tumour cells by ethyleneimines. Biochem J 63:300–307

    PubMed  CAS  Google Scholar 

  6. Shall S (1982) ADP-Ribose in DNA repair. In: Hayaishi O, Ueda K (eds) ADP-ribosylation reactions. Academic, New York, pp 477–520, Chapter 29

    Google Scholar 

  7. Shall S (1975) Experimental manipulation of the specific activity of poly (ADP-ribose) polymerase. J Biol Chem (Tokyo) 77:2

    Google Scholar 

  8. Skidmore CJ, Davies MI, Goodwin PM, Halldorsson H, Lewis PJ, Shall S (1979) The involvement of poly (ADP-ribose) polymerase in the degradation of NAD caused by γ-radiation and N-methyl-N-nitrosourea. Eur J Biochem 101:135–142

    Article  PubMed  CAS  Google Scholar 

  9. Durkacz BW, Omidiji O, Gray DA, Shall S (1980) (ADP-Ribose) n participates in DNA repair. Nature 283:593–596

    Article  PubMed  CAS  Google Scholar 

  10. Shall S (1983) ADP-ribose in DNA repair: a new component of DNA excision repair. Adv Rad Biol 11:1–69

    Google Scholar 

  11. Shall S (1984) Inhibition of DNA repair by inhibitors of nuclear ADP-ribosyl transferase. Nucleic Acids Symp Ser 13:143–191

    PubMed  CAS  Google Scholar 

  12. Shall S (2000) Pespectives. In: de Murcia G, Shall S (eds) From DNA damage and stress signaling to cell death; poly ADP-ribose reactions. Oxford University Press, Oxford, Chapter 7, 238pp

    Google Scholar 

  13. Bowman KJ, White A, Golding BT et al (1998) Potentiation of anticancer agent cytotoxicity by the potent poly (ADP-ribose) polymerase inhibitors, NU-1025 and NU-1064. Br J Cancer 78:1269–1277

    Article  PubMed  CAS  Google Scholar 

  14. White AW, Curtin NJ, Eastman BW, Golding BT, Hostomsky Z, Kyle S, Li J-K, Maegley KA, Skalitzky DJ, Webber SE, Yu X-H, Griffin RJ (2004) Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorg Med Chem 14:2433–2437

    Article  CAS  Google Scholar 

  15. Delaney CA, Wang LZ, Kyle S, Srinivasan S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, Maegley K, Golding BT, Griffin RG, Newell DR (2000) Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly (adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 6:2860–2867

    PubMed  CAS  Google Scholar 

  16. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, North M, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang L-Z, Webber SE, Williams KJ, Curtin NJ (2004) Preclinical evaluation of a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, AG14361, with significant anticancer chemo- and radio-sensitization activity. J Natl Cancer Inst 96:56–67

    Article  PubMed  CAS  Google Scholar 

  17. Canan Koch SS, Thoresen L, Tikhe JG et al (2002) Novel tricyclic poly (ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J Med Chem 45:4961–4964

    Article  PubMed  Google Scholar 

  18. Plummer R, Jones C, Middleton M et al (2008) Phase 1 study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14:7917–7923

    Article  PubMed  CAS  Google Scholar 

  19. Helleday T (2010) Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 31(6):955–960

    Article  PubMed  CAS  Google Scholar 

  20. Evers B, Helleday T, Jonkers J (2010) Targeting homologous recombination repair defects in cancer. Trends Pharmacol Sci 31:372–380

    Article  PubMed  CAS  Google Scholar 

  21. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917

    Article  PubMed  CAS  Google Scholar 

  22. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Knights C, Martin NMB, Jackson SP, Smith GCM, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921

    Article  PubMed  CAS  Google Scholar 

  23. Fong PC, Boss DS, Yap TA, Tutt A, Wu P-J, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS (2009) Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134

    Article  PubMed  CAS  Google Scholar 

  24. Gaymes TJ, Shall S, Farzaneh F, Mufti GJ (2008) Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors. Haematologica 93(12):1886–1889

    Article  PubMed  CAS  Google Scholar 

  25. Gaymes TJ, Shall S, MacPherson LJ, Twine NA, Lea NC, Farzaneh F, Mufti GJ (2009) Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukaemia and myelodysplastic syndromes. Haematologica 94(5):638–646

    Article  PubMed  CAS  Google Scholar 

  26. Mohamedali AM, Smith AE, Gäken J, Lea NC, Mian SA, Westwood NB, Strupp C, Gattermann N, Germing U, Mufti GJ (2009) Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 27:4002–4006

    Article  PubMed  CAS  Google Scholar 

  27. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z-Y, Gäken J, Lea NC, Przychodzen B, Mian SA, Nasser EE, Shooter C, Westwood NB, Strupp C, Gattermann N, Maciejewski JP, Germing U, Mufti GJ (2010) Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 116:3923–3932

    Article  PubMed  CAS  Google Scholar 

  28. Mukhopadhyay A, Elatter A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ, Curtin NJ (2010) Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to PARP inhibitors. Clin Cancer Res 16:2344–2351

    Article  PubMed  CAS  Google Scholar 

  29. Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A (2008) A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair 7:2010–2019

    Article  PubMed  CAS  Google Scholar 

  30. Loeb LA, Springgate CF, Battula N (1974) Errors in DNA replication as a basis of malignant change. Cancer Res 34:2311–2321

    PubMed  CAS  Google Scholar 

  31. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA (2006) Human cancers express a mutator phenotype. Proc Natl Acad Sci USA 103:18238–18242

    Article  PubMed  CAS  Google Scholar 

  32. Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T (2010) The PARP inhibitor olaparib induces significant killing of ATM deficient lymphoid tumor cells in vitro and in vivo. Blood 116(22):4578–4587

    Article  PubMed  CAS  Google Scholar 

  33. Olive PI, Banáth JP (2006) The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 1(1):23–29

    Article  PubMed  CAS  Google Scholar 

  34. Shaposhnikov S, Frengen E, Collins AR (2009) increasing the resolution of the comet assay using fluorescent in situ hybridization – a review. Mutagenesis 24(5):382–389

    Article  Google Scholar 

  35. Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, Hamelin R (2002) Evaluation of tumor microsatellite instability using five quasi-monomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123(6):1804–1811

    Article  PubMed  CAS  Google Scholar 

  36. Shall S (1983) ADP-ribosylation, DNA repair, cell differentiation and cancer. In: Miwa M, Hayaishi O, Shall S, Smulson M, Sugimura T (eds) ADP-ribosylation, DNA repair and cancer. Japan Sci. Soc. Press/VNU Science Press, Tokyo/Utrecht, pp 3–25

    Google Scholar 

  37. Gaymes TJ, Padua RA, Pla M, Orr S, Omidvar N, Chomienne C, Mufti GJ, Rassool FV (2006) Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? Mol Cancer Res 4(8):563–573

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematological Medicine, The Rayne Institute, Kings College London, Denmark Hill Campus, London, UK

    Sydney Shall & Farzin Farzaneh

  2. Leukaemia Sciences Laboratories, Department of Haematological Medicine, The Rayne Institute, Kings College London, Denmark Hill Campus, London, UK

    Terry Gaymes & Ghulam J. Mufti

  3. Northern Institute for Cancer Research, University of Newcastle Upon Tyne, Newcastle Upon Tyne, UK

    Nicola Curtin

Authors
  1. Sydney Shall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Terry Gaymes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Farzin Farzaneh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicola Curtin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ghulam J. Mufti
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Keystone Program in Epigenetics &, Progenitor Cells, Fox Chase Cancer Center, Cottman Avenue 333, Philadelphia, 19111, Pennsylvania, USA

    Alexei V. Tulin

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Shall, S., Gaymes, T., Farzaneh, F., Curtin, N., Mufti, G.J. (2011). The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy; Use as a Single Agent in Susceptible Patients; Techniques Used to Identify Susceptible Patients . In: Tulin, A. (eds) Poly(ADP-ribose) Polymerase. Methods in Molecular Biology, vol 780. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-270-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-270-0_15

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-269-4

  • Online ISBN: 978-1-61779-270-0

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation